Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin and 5FU in 5FU-Resistant Metastatic Colon Cancer
NCT02724202Phase 1Terminated
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Feb 2018
- Primary completion
- Jan 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of curcumin in colon cancer, sponsored by Baylor Scott & White Research Institute. Primary endpoint: Incidence of Adverse Events at 12 weeks. Started Feb 2018; status: terminated.
02
Drugs
curcumin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02724202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724202.